This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2002 Apr:28 Suppl A:1-2.

doi: 10.1016/s0305-7372(02)80001-9.

Clinical benefits of pegylated proteins in oncology

PMID: 12173406
DOI: 10.1016/s0305-7372(02)80001-9

Review

Clinical benefits of pegylated proteins in oncology

J Crawford. Cancer Treat Rev. 2002 Apr.

. 2002 Apr:28 Suppl A:1-2.

doi: 10.1016/s0305-7372(02)80001-9.

Author

PMID: 12173406
DOI: 10.1016/s0305-7372(02)80001-9

No abstract available

PubMed Disclaimer

Similar articles

Pegylation: engineering improved pharmaceuticals for enhanced therapy.
Molineux G. Molineux G. Cancer Treat Rev. 2002 Apr;28 Suppl A:13-6. doi: 10.1016/s0305-7372(02)80004-4. Cancer Treat Rev. 2002. PMID: 12173407 Review.
Clinical uses of pegylated pharmaceuticals in oncology.
Crawford J. Crawford J. Cancer Treat Rev. 2002 Apr;28 Suppl A:7-11. doi: 10.1016/s0305-7372(02)80003-2. Cancer Treat Rev. 2002. PMID: 12173409 Review.
Novel effects with polyethylene glycol modified pharmaceuticals.
Yowell SL, Blackwell S. Yowell SL, et al. Cancer Treat Rev. 2002 Apr;28 Suppl A:3-6. doi: 10.1016/s0305-7372(02)80002-0. Cancer Treat Rev. 2002. PMID: 12173408 Review.
Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF. Youngster S, et al. Curr Pharm Des. 2002;8(24):2139-57. doi: 10.2174/1381612023393242. Curr Pharm Des. 2002. PMID: 12369859 Review.
Pegfilgrastim: a new therapy to prevent neutropenic fever.
Bence AK, Adams VR. Bence AK, et al. J Am Pharm Assoc (Wash). 2002 Sep-Oct;42(5):806-8. doi: 10.1331/108658002764653595. J Am Pharm Assoc (Wash). 2002. PMID: 12269716 No abstract available.

See all similar articles

Cited by

Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
Schafer ES, Rushing T, Crews KR, Annesley C, Colace SI, Kaiser N, Pommert L, Ramsey LB, Sabnis HS, Wong K, Chang BH, Cooper TM, Shah NN, Rheingold SR, Place AE, Chi YY, Bhojwani D, Wayne AS, Bernhardt MB. Schafer ES, et al. J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165. J Natl Cancer Inst. 2024. PMID: 38964343 Free PMC article.
Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia.
Wu FP, Wang J, Wang H, Li N, Guo Y, Cheng YJ, Liu Q, Yang XR. Wu FP, et al. Exp Ther Med. 2015 Mar;9(3):761-765. doi: 10.3892/etm.2014.2160. Epub 2014 Dec 30. Exp Ther Med. 2015. PMID: 25667625 Free PMC article.
Onto better TRAILs for cancer treatment.
de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. de Miguel D, et al. Cell Death Differ. 2016 May;23(5):733-47. doi: 10.1038/cdd.2015.174. Epub 2016 Mar 4. Cell Death Differ. 2016. PMID: 26943322 Free PMC article. Review.
Ultrasound for the treatment of acute kidney injury and other inflammatory conditions: a promising path toward noninvasive neuroimmune regulation.
Cai J, Nash WT, Okusa MD. Cai J, et al. Am J Physiol Renal Physiol. 2020 Jul 1;319(1):F125-F138. doi: 10.1152/ajprenal.00145.2020. Epub 2020 Jun 8. Am J Physiol Renal Physiol. 2020. PMID: 32508112 Free PMC article.
Therapeutic targeting of TRAIL death receptors.
Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, Srinivasan P, Strandberg J, Hahn M, Sanchez Sevilla Uruchurtu A, Seyhan AA, Carneiro BA, Zhou L, Huntington KE, El-Deiry WS. Di Cristofano F, et al. Biochem Soc Trans. 2023 Feb 27;51(1):57-70. doi: 10.1042/BST20220098. Biochem Soc Trans. 2023. PMID: 36629496 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science